866-997-4948(US-Canada Toll Free)

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals-Q3 2017

Published By :

GlobalData

Published Date : Nov 2017

Category :

Pharmaceutical

No. of Pages : 95 Pages

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2017

Summary

GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2017", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q3 2017. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalDatas proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

The pharmaceutical and healthcare industry reported a decrease in the number of deals and deal values in Q3 2017 with 1,077 deals worth USD90.3 billion, as compared 1,113 worth USD114.1 billion in Q3 2016. On a quarter-on-quarter basis, the number of deals and deal values decreased in Q3 2017, when compared to 1,153 deals worth USD92.3 billion in Q2 2017. The pharmaceutical and healthcare industry reported a decrease in upfront payments in licensing agreements with USD347.3m in Q3 2017, as compared USD753.8m in Q3 2016. On a quarter-on-quarter basis, the upfront payments reported a decrease in Q3 2017, when compared to USD735.8m in Q2 2017. Deals in oncology therapeutics market registered a decrease with 362 deals in Q3 2017, compared to 392 deals in Q2 2017. North America reported a decrease in the number of deals from 726 in Q2 2017 to 676 in Q3 2017.

Scope

- Analysis of the market trends for the pharmaceutical industry in the global arena.
- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
- Analysis of partnership and licensing deals based on clinical stage of development of products.
- Summary of the pharmaceutical deals globally in the five quarters.
- Information on the top deals happened in the pharmaceutical industry.
- Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing segments for investments in your industry.
- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
- Identify companies that are aggressively looking to raise capital in the market
- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
- Identify growth segments and opportunities in each region within the industry.
- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 7
2 Pharmaceuticals & Healthcare, Global, Deal Summary, Q3 2017 10
2.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, Q3 2017 10
2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, Q3 2017 12
2.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, Q3 2017 13
2.4 Pharmaceuticals & Healthcare, Global, Top Deals, Q3 2017 14
2.4.1 Gilead Sciences Acquires Kite Pharma for USD11.9 Billion 14
2.4.2 AstraZeneca Enters into Agreement with Merck 15
2.4.3 Baotou Dongbao Bio Tech to Raise up to USD5.6 Billion in Private Placement of Shares 16
2.4.4 Sanofi Enters into Licensing Agreement with Ablynx 16
2.4.5 Gilead Sciences Raises USD3 Billion in Public Offering of Notes 16
3 Pharmaceuticals & Healthcare, Global, Deals Summary, by Type 17
3.1 Pharmaceuticals & Healthcare, Global, M&A, Q3 2017 17
3.1.1 Top M&A Deals in Q3 2017 18
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, Q3 2016 - Q3 2017 19
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q3 2017 20
3.2.1 Top Initial Public Offerings in Q3 2017 21
3.2.2 Top Secondary Offerings in Q3 2017 21
3.2.3 Top PIPE Deals in Q3 2017 22
3.2.4 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q3 2016 - Q3 2017 22
3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, Q3 2017 24
3.3.1 Top Venture Financing Deals in Q3 2017 25
3.3.2 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q3 2017 25
3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q3 2017 26
3.3.4 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, Q3 2016 - Q3 2017 27
3.3.5 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Q3 2016 - Q3 2017 28
3.3.6 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q3 2016 - Q3 2017 29
3.4 Pharmaceuticals & Healthcare, Global, Private Equity Deals, Q3 2017 30
3.4.1 Top Private Equity Deals in Q3 2017 31
3.4.2 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Q3 2016 - Q3 2017 31
4 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q3 2017 33
4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q3 2017 33
4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q3 2016 - Q3 2017 34
4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2017 35
4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, Q3 2017 36
4.3.2 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q3 2017 36
4.3.3 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payments, Q3 2017 37
4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2016 - Q3 2017 38
4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, Q3 2016 - Q3 2017 39
4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), Q3 2016 - Q3 2017 40
4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2016 - Q3 2017 41
5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q3 2017 43
5.1 Pharmaceutical & Healthcare, Global, Licensing Agreements, Q3 2017 43
5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2016 - Q3 2017 44
5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Value, Q3 2017 45
5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, Q3 2017 45
5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q3 2017 46
5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q3 2016 - Q3 2017 46
5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (US$ m), Q3 2016 - Q3 2017 48
5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q3 2016 - Q3 2017 50
5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q3 2016 - Q3 2017 51
5.7 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (US$ m), Q3 2016 - Q3 2017 53
6 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 55
6.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, Q3 2017 55
6.1.1 Oncology - Deals of the Quarter 56
6.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, Q3 2017 58
6.2.1 Central Nervous System - Deals of the Quarter 59
6.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, Q3 2017 61
6.3.1 Infectious Disease - Deals of the Quarter 62
6.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, Q3 2017 64
6.4.1 Immunology - Deals of the Quarter 65
6.5 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, Q3 2017 67
6.5.1 Metabolic Disorders - Deals of the Quarter 68
6.6 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, Q3 2017 70
6.6.1 Cardiovascular - Deals of the Quarter 71
6.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, Q3 2017 72
6.7.1 Gastrointestinal - Deals of the Quarter 74
6.8 Pharmaceuticals & Healthcare, Global, Musculoskeletal Disorders Deals, Q3 2017 75
6.8.1 Musculoskeletal Disorders - Deals of the Quarter 76
6.9 Pharmaceuticals & Healthcare, Global, Respiratory Deals, Q3 2017 77
6.9.1 Respiratory - Deals of the Quarter 79
6.10 Pharmaceuticals & Healthcare, Global, Dermatology Deals, Q3 2017 80
6.10.1 Dermatology - Deals of the Quarter 81
7 Deal Summary by Geography 82
7.1 Pharmaceuticals & Healthcare, North America Region, Deals, Q3 2017 82
7.1.1 North America - Deals of the Quarter 83
7.2 Pharmaceuticals & Healthcare, Europe Region, Deals, Q3 2017 85
7.2.1 Europe - Deals of the Quarter 86
7.3 Pharmaceuticals & Healthcare, Asia-Pacific, Deals, Q3 2017 87
7.3.1 Asia-Pacific - Deals of the Quarter 88
7.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, Q3 2017 89
7.4.1 Rest of the World - Deals of the Quarter 90
8 Pharmaceuticals & Healthcare, Global, Top Advisors 91
8.1 Pharmaceuticals & Healthcare, Global Top Financial Advisors, M&A, Q3 2016 - Q3 2017 91
8.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Q3 2016 - Q3 2017 92
9 Further Information 93
9.1 Methodology 93
9.2 About GlobalData 94
9.3 Contact Us 94
9.4 Disclosure information 94
9.5 Disclaimer 95

1.1 List of Tables
Table 1: Pharmaceuticals & Healthcare, Global, Deal Summary, Number of Deals and Deal Values (US$m), Q3 2016 - Q3 2017 11
Table 2: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), Q3 2017 13
Table 3: Pharmaceuticals & Healthcare, Global, Top Deals, Q3 2017 14
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017 18
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, Q3 2017 18
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, , Q3 2016 - Q3 2017 19
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2016 - Q3 2017 21
Table 8: Pharmaceuticals & Healthcare, Global, Top Initial Public Offering Deals, Q3 2017 21
Table 9: Pharmaceuticals & Healthcare, Global, Top Secondary Offering Deals, Q3 2017 21
Table 10: Pharmaceuticals & Healthcare, Global, Top PIPE Deals, Q3 2017 22
Table 11: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2016 - Q3 2017 23
Table 12: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017 24
Table 13: Pharmaceuticals & Healthcare, Global, Top Venture Capital Deals, Q3 2017 25
Table 14: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Values (%), Q3 2017 26
Table 15: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2016 - Q3 2017 27
Table 16: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017 28
Table 17: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q3 2016 - Q3 2017 29
Table 18: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017 30
Table 19: Pharmaceuticals & Healthcare, Global, Top Private Equity Deals, Q3 2017 31
Table 20: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2016 - Q3 2017 32
Table 21: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017 33
Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017 34
Table 23: Pharmaceuticals & Healthcare, Partnership Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2016 - Q3 2017 35
Table 24: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2017 36
Table 25: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q3 2017 36
Table 26: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, Q3 2017 37
Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q3 2016 - Q3 2017 38
Table 28: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2016 - Q3 2017 40
Table 29: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Values (US$ m), Q3 2016 - Q3 2017 42
Table 30: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deal Summary, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017 43
Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2016 - Q3 2017 44
Table 32: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Deal Values, Q3 2017 45
Table 33: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Upfront Payment, Q3 2017 45
Table 34: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Milestone Payment, Q3 2017 46
Table 35: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017 47
Table 36: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment (US$ m), Q3 2016 - Q3 2017 49
Table 37: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2016 - Q3 2017 52
Table 38: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment and Deal Values (US$ m), Q3 2016 - Q3 2017 54
Table 39: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017 56
Table 40: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017 59
Table 41: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017 62
Table 42: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017 65
Table 43: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017 68
Table 44: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017 71
Table 45: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017 73
Table 46: Pharmaceuticals & Healthcare, Global, Musculoskeletal Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017 76
Table 47: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017 78
Table 48: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017 81
Table 49: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017 83
Table 50: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017 86
Table 51: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017 88
Table 52: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017 90
Table 53: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017 91
Table 54: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017 92

1.2 List of Figures
Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$m), Q3 2016 - Q3 2017 10
Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), Q3 2017 12
Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), Q3 2017 13
Figure 4: Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$m), Q3 2016 - Q3 2017 17
Figure 5: Pharmaceuticals & Healthcare, Global, M&As, by Therapy Area, Number of Deals and Deal Values (US$m), by Therapy Area, Q3 2016 - Q3 2017 19
Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017 20
Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$m), , Q3 2016 - Q3 2017 22
Figure 8: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017 24
Figure 9: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%), Q3 2017 25
Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Deal Values (%), Q3 2017 26
Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q3 2016 - Q3 2017 27
Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017 28
Figure 13: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017 30
Figure 14: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q3 2016 - Q3 2017 31
Figure 15: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017 33
Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017 34
Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront & Milestone Payment and Deal Values (US$ m), Q3 2016 - Q3 2017 35
Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q3 2016 - Q3 2017 38
Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2016 - Q3 2017 39
Figure 20: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2016 - Q3 2017 40
Figure 21: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payment and Deal Values (US$ m), Q3 2016 - Q3 2017 41
Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017 43
Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2016 - Q3 2017 44
Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017 46
Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2016 - Q3 2017 48
Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Number Of Deals, Q3 2016 - Q3 2017 50
Figure 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Deal Values (US$ m), Q3 2016 - Q3 2017 51
Figure 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2016 - Q3 2017 53
Figure 29: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017 55
Figure 30: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017 58
Figure 31: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017 61
Figure 32: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017 64
Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017 67
Figure 34: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017 70
Figure 35: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017 72
Figure 36: Pharmaceuticals & Healthcare, Global, Musculoskeletal Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017 75
Figure 37: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017 77
Figure 38: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017 80
Figure 39: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017 82
Figure 40: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017 85
Figure 41: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017 87
Figure 42: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017 89
Figure 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017 91
Figure 44: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q3 2016 - Q3 2017 92

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *